Heparan sulfate proteoglycans and cancer

Abstract

Heparan sulfate proteoglycans (HSPGs) are widely distributed in mammalian tissues and involved in a number of processes related to malignancy. They are composed of a core protein to which chains of the glycosaminoglycan, heparan sulfate (HS), are attached. The existence of various classes of core protein, in addition to highly polymorphic HS chains, creates a superfamily of macromolecules with considerable diversity of structure and function. HSPGs interact with many proteins including growth factors, chemokines and structural proteins of the extracellular matrix to influence cell growth, differentiation, and the cellular response to the environment. The recent identification of two inherited syndromes that are associated with an increased cancer risk, and caused by mutations in HSPG-related genes, has intensified interest in these molecules. This review describes our current understanding of HSPGs in cancer and highlights new possibilities for therapeutic control.

References 36

1. 1.

   Alexander C. M., Reichsman F., Hinkes M. T., Lincecum J., Becker K. A., Cumberledge S., Bernfield M. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet. 2000;25(3):329-332.

   Not in our library10.1038/77108

2. 2.

   Arai T., Akiyama Y., Nagasaki H., Murase N., Okabe S., Ikeuchi T., Saito K., Iwai T., Yuasa Y. EXTL3/EXTR1 alterations in colorectal cancer cell lines. Int J Oncol. 1999;15(5):915-919.

   Not in our library10.3892/ijo.15.5.915

3. 3.

   Aviezer D., Iozzo R. V., Noonan D. M., Yayon A. Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense cDNA. Mol Cell Biol. 1997;17(4):1938-1946.

   Not in our library10.1128/mcb.17.4.1938

4. 4.

   Bernfield M., Götte M., Park P. W., Reizes O., Fitzgerald M. L., Lincecum J., Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999;68:729-777.

   Not in our library10.1146/annurev.biochem.68.1.729

5. 5.

   Chang Z., Meyer K., Rapraeger A. C., Friedl A. Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex in situ. FASEB J. 2000;14(1):137-144.

   Not in our library10.1096/fasebj.14.1.137

6. 6.

   Choi C., Cho S., Horikawa I., Berchuck A., Wang N., Cedrone E., Jhung S. W., Lee J. B., Kerr J., Chenevix-Trench G. Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas. Genes Chromosomes Cancer. 1997;20(3):234-242.

   Not in our library

7. 7.

   Conejo J. R., Kleeff J., Koliopanos A., Matsuda K., Zhu Z. W., Goecke H., Bicheng N., Zimmermann A., Korc M., Friess H. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer. 2000;88(1):12-20.

   Not in our library10.1002/1097-0215(20001001)88:1<12::aid-ijc3>3.0.co;2-t

8. 8.

   Dhodapkar M. V., Abe E., Theus A., Lacy M., Langford J. K., Barlogie B., Sanderson R. D. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood. 1998;91(8):2679-2688.

   Not in our library

9. 9.

   Gonzalez A. D., Kaya M., Shi W., Song H., Testa J. R., Penn L. Z., Filmus J. OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. J Cell Biol. 1998;141(6):1407-1414.

   Not in our library10.1083/jcb.141.6.1407

10. 10.

    Hecht J. T., Hogue D., Strong L. C., Hansen M. F., Blanton S. H., Wagner M. Hereditary multiple exostosis and chondrosarcoma: linkage to chromosome II and loss of heterozygosity for EXT-linked markers on chromosomes II and 8. Am J Hum Genet. 1995;56(5):1125-1131.

    Not in our library

11. 11.

    Hennekam R. C. Hereditary multiple exostoses. J Med Genet. 1991;28(4):262-266.

    Not in our library10.1136/jmg.28.4.262

12. 12.

    Jayson G. C., Lyon M., Paraskeva C., Turnbull J. E., Deakin J. A., Gallagher J. T. Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J Biol Chem. 1998;273(1):51-57.

    Not in our library10.1074/jbc.273.1.51

13. 13.

    Kitagawa H., Shimakawa H., Sugahara K. The tumor suppressor EXT-like gene EXTL2 encodes an alpha1, 4-N-acetylhexosaminyltransferase that transfers N-acetylgalactosamine and N-acetylglucosamine to the common glycosaminoglycan-protein linkage region. The key enzyme for the chain initiation of heparan sulfate. J Biol Chem. 1999;274(20):13933-13937.

    Not in our library10.1074/jbc.274.20.13933

14. 14.

    Kleeff J., Ishiwata T., Kumbasar A., Friess H., Büchler M. W., Lander A. D., Korc M. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest. 1998;102(9):1662-1673.

    Not in our library10.1172/jci4105

15. 15.

    Kumar-Singh S., Jacobs W., Dhaene K., Weyn B., Bogers J., Weyler J., Van Marck E. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. J Pathol. 1998;186(3):300-305.

    Not in our library10.1002/(sici)1096-9896(1998110)186:3<300::aid-path180>3.0.co;2-q

16. 16.

    Lin H., Huber R., Schlessinger D., Morin P. J. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res. 1999;59(4):807-810.

    Not in our library

17. 17.

    Lind T., Tufaro F., McCormick C., Lindahl U., Lidholt K. The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem. 1998;273(41):26265-26268.

    Not in our library10.1074/jbc.273.41.26265

18. 18.

    Lindahl U., Kusche-Gullberg M., Kjellén L. Regulated diversity of heparan sulfate. J Biol Chem. 1998;273(39):24979-24982.

    Not in our library10.1074/jbc.273.39.24979

19. 19.

    Matsumoto A., Ono M., Fujimoto Y., Gallo R. L., Bernfield M., Kohgo Y. Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer. 1997;74(5):482-491.

    Not in our library10.1002/(sici)1097-0215(19971021)74:5<482::aid-ijc2>3.0.co;2-#

20. 20.

    McCormick C., Leduc Y., Martindale D., Mattison K., Esford L. E., Dyer A. P., Tufaro F. The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nat Genet. 1998;19(2):158-161.

    Not in our library10.1038/514

21. 21.

    McKenzie E., Tyson K., Stamps A., Smith P., Turner P., Barry R., Hircock M., Patel S., Barry E., Stubberfield C. Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem Biophys Res Commun. 2000;276(3):1170-1177.

    Not in our library10.1006/bbrc.2000.3586

22. 22.

    Merry C. L., Lyon M., Deakin J. A., Hopwood J. J., Gallagher J. T. Highly sensitive sequencing of the sulfated domains of heparan sulfate. J Biol Chem. 1999;274(26):18455-18462.

    Not in our library10.1074/jbc.274.26.18455

23. 23.

    Murthy S. S., Shen T., De Rienzo A., Lee W. C., Ferriola P. C., Jhanwar S. C., Mossman B. T., Filmus J., Testa J. R. Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene. 2000;19(3):410-416.

    Not in our library10.1038/sj.onc.1203322

24. 24.

    Nackaerts K., Verbeken E., Deneffe G., Vanderschueren B., Demedts M., David G. Heparan sulfate proteoglycan expression in human lung-cancer cells. Int J Cancer. 1997;74(3):335-345.

    Not in our library10.1002/(sici)1097-0215(19970620)74:3<335::aid-ijc18>3.0.co;2-a

25. 25.

    Paine-Saunders S., Viviano B. L., Zupicich J., Skarnes W. C., Saunders S. glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development. Dev Biol. 2000;225(1):179-187.

    Not in our library10.1006/dbio.2000.9831

26. 26.

    Pilia G., Hughes-Benzie R. M., MacKenzie A., Baybayan P., Chen E. Y., Huber R., Neri G., Cao A., Forabosco A., Schlessinger D. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet. 1996;12(3):241-247.

    Not in our library10.1038/ng0396-241

27. 27.

    Pye D. A., Vives R. R., Turnbull J. E., Hyde P., Gallagher J. T. Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity. J Biol Chem. 1998;273(36):22936-22942.

    Not in our library10.1074/jbc.273.36.22936

28. 28.

    Raskind W. H., Conrad E. U., Chansky H., Matsushita M. Loss of heterozygosity in chondrosarcomas for markers linked to hereditary multiple exostoses loci on chromosomes 8 and 11. Am J Hum Genet. 1995;56(5):1132-1139.

    Not in our library

29. 29.

    Seidel C., Sundan A., Hjorth M., Turesson I., Dahl I. M., Abildgaard N., Waage A., Borset M. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood. 2000;95(2):388-392.

    Not in our library

30. 30.

    Selleck S. B. Proteoglycans and pattern formation: sugar biochemistry meets developmental genetics. Trends Genet. 2000;16(5):206-212.

    Not in our library10.1016/s0168-9525(00)01997-1

31. 31.

    Sharma B., Handler M., Eichstetter I., Whitelock J. M., Nugent M. A., Iozzo R. V. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest. 1998;102(8):1599-1608.

    Not in our library10.1172/jci3793

32. 32.

    Stanley M. J., Stanley M. W., Sanderson R. D., Zera R. Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am J Clin Pathol. 1999;112(3):377-383.

    Not in our library10.1093/ajcp/112.3.377

33. 33.

    Stickens D., Brown D., Evans G. A. EXT genes are differentially expressed in bone and cartilage during mouse embryogenesis. Dev Dyn. 2000;218(3):452-464.

    Not in our library10.1002/1097-0177(200007)218:3<452::aid-dvdy1000>3.0.co;2-p

34. 34.

    Veugelers M., Cat B. D., Muyldermans S. Y., Reekmans G., Delande N., Frints S., Legius E., Fryns J. P., Schrander-Stumpel C., Weidle B. Mutational analysis of the GPC3/GPC4 glypican gene cluster on Xq26 in patients with Simpson-Golabi-Behmel syndrome: identification of loss-of-function mutations in the GPC3 gene. Hum Mol Genet. 2000;9(9):1321-1328.

    Not in our library10.1093/hmg/9.9.1321

35. 35.

    Vlodavsky I., Friedmann Y., Elkin M., Aingorn H., Atzmon R., Ishai-Michaeli R., Bitan M., Pappo O., Peretz T., Michal I. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med. 1999;5(7):793-802.

    Not in our library10.1038/10518

36. 36.

    van Kuppevelt T. H., Dennissen M. A., van Venrooij W. J., Hoet R. M., Veerkamp J. H. Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J Biol Chem. 1998;273(21):12960-12966.

    Not in our library10.1074/jbc.273.21.12960

Cited by papers we hold 6

• Natural Killer cells at the frontline in the fight against cancer · 2024
  No notice
• The Uncovered Role of Immune Cells and NK Cells in the Regulation of Bone Metastasis · 2019
  Not checked
• Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers · 2018
  No notice
• Syndecan-3 and TFPI colocalize on the surface of endothelial-, smooth muscle-, and cancer cells. · 2015
  Not checked
• Neuropathology in Mouse Models of Mucopolysaccharidosis Type I, IIIA and IIIB · 2012
  No notice
• Minimus: a fast, lightweight genome assembler · 2007
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.